)
Visual24 Oct 2025
The rise of Alphabet
Relmada Therapeutics (RLMD) investor relations material
Relmada Therapeutics Small-Cap Virtual Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Small-Cap Virtual Conference summary18 Sep, 2025
Strategic updates and program focus
Shifted to lower-risk programs, acquiring two new assets this year to drive near-term value.
NDB-01, an extended-release intravesical chemotherapy gel for non-muscle invasive bladder cancer, is the most advanced asset and main value driver for the next 1-2 years.
Sopranolol, a subcutaneous injection for compulsive disorders, is being advanced for Prader-Willi syndrome with phase 2 planned for late H1 next year.
NDB-01 clinical and market positioning
NDB-01 delivers gemcitabine and docetaxel via a gel matrix, enabling easier, faster, and safer administration in a doctor's office.
Phase 2 open-label study shows 90% of patients cancer-free at six months, a rate described as the highest seen in this indication.
Competing products from Johnson & Johnson and UroGen have higher costs ($120,000–$690,000/year) and logistical limitations; NDB-01 aims to be more convenient and cost-effective.
Registration study for NDB-01 is planned to start in Q2 next year, with completion targeted for 2027.
Financial overview and capital strategy
End of Q2 cash and equivalents totaled $20.6 million, with 33.2 million shares outstanding and an unlevered balance sheet.
Additional financing will be needed to support clinical milestones, but not immediately; management is mindful of share price and value creation.
Recent insider buying by CEO and Chief Medical Officer signals management confidence.
NDB-01's competitive edge vs. J&J and UroGen?
Financial runway to next major NDB-01 milestone?
What makes NDB-01's 90% efficacy unique?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Relmada Therapeutics earnings date
Q3 20256 Nov, 2025
Next Relmada Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focusing on developing innovative treatments for central nervous system (CNS) diseases, with a particular emphasis on major depressive disorder. The company's flagship product, esmethadone (d-methadone, dextromethadone, REL-1017), is a novel N-methyl-D-aspartate (NMDA) receptor antagonist currently inclinical trials, aimed at serving as an adjunctive or monotherapy treatment for MDD in adults. The company is headquartered Coral Gables, Florida. Its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage